Bioscience division drives sales growth at Grifols

6 May 2016

Spanish drugmaker Grifols reported increased its net revenues for the first quarter of 2016 increased by 5.6% (+1.5% constant currency) to Euros 958.9 million euros ($1.1 billion) in the first quarter of 2016. Recurring sales (excluding Raw Materials and Others) grew by 7.1% (+2.9% cc), with revenues of 938.8 million euros.

The Bioscience Division was the main driver of growth, with revenues rising 10.9% (+6.3% cc) to 754.9 million euros. The demand for plasma proteins continued its upward trend, with growth in the main proteins and a notable contribution from sales of alpha-1 antitrypsin and albumin. The company maintained the leadership position of its IVIG at global level.

Revenues of the Diagnostic Division amounted to 161.0 million euros, decreasing by 6.7% (-9.9% cc). Revenues of the Hospital Division were stable at 22.8 million euros compared with 23.3 million euros for the same period of 2015, falling by 1.8% (-1.2% cc).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK